MX2020011769A - Derivados de sulfonamida novedosos que tienen actividad inhibidora selectiva de nox. - Google Patents

Derivados de sulfonamida novedosos que tienen actividad inhibidora selectiva de nox.

Info

Publication number
MX2020011769A
MX2020011769A MX2020011769A MX2020011769A MX2020011769A MX 2020011769 A MX2020011769 A MX 2020011769A MX 2020011769 A MX2020011769 A MX 2020011769A MX 2020011769 A MX2020011769 A MX 2020011769A MX 2020011769 A MX2020011769 A MX 2020011769A
Authority
MX
Mexico
Prior art keywords
inhibiting activity
sulfonamide derivatives
novel sulfonamide
selective nox
compound
Prior art date
Application number
MX2020011769A
Other languages
English (en)
Inventor
Per Wikström
Erik Walum
Original Assignee
Glucox Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glucox Biotech Ab filed Critical Glucox Biotech Ab
Publication of MX2020011769A publication Critical patent/MX2020011769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Abstract

Se describe un compuesto de la fórmula (I) (ver Fórmula) o una sal farmacéuticamente aceptable del mismo. El compuesto es útil en la terapia, por ejemplo para el tratamiento de una afección o trastorno asociado con actividad de nicotinamida adenina dinucleótido fosfato oxidasa 4 o 2 (Nox4 o Nox2). Una composición farmacéutica que comprende el compuesto.
MX2020011769A 2018-05-09 2019-05-09 Derivados de sulfonamida novedosos que tienen actividad inhibidora selectiva de nox. MX2020011769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18171556 2018-05-09
PCT/EP2019/061950 WO2019215291A1 (en) 2018-05-09 2019-05-09 Novel sulfonamide derivatives having selective nox inhibiting activity

Publications (1)

Publication Number Publication Date
MX2020011769A true MX2020011769A (es) 2021-01-29

Family

ID=62148213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011769A MX2020011769A (es) 2018-05-09 2019-05-09 Derivados de sulfonamida novedosos que tienen actividad inhibidora selectiva de nox.

Country Status (10)

Country Link
US (1) US20210171456A1 (es)
EP (1) EP3790858A1 (es)
JP (1) JP7455762B2 (es)
KR (1) KR20210008493A (es)
CN (1) CN112384497A (es)
AU (1) AU2019267105A1 (es)
BR (1) BR112020022406A2 (es)
CA (1) CA3099093A1 (es)
MX (1) MX2020011769A (es)
WO (1) WO2019215291A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217764A1 (en) 2022-05-09 2023-11-16 Calliditas Therapeutics Suisse Sa Nox inhibitors for use in the treatment of alport syndrome
KR20240002032A (ko) 2022-06-28 2024-01-04 동국대학교 산학협력단 Nadph 산화효소 2 저해제로서의 신규 화합물 및 이를 포함하는 약학조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
AU2007276885A1 (en) * 2006-07-25 2008-01-31 Sanofi-Aventis 2-phenyl-indoles as prostaglandin D2 receptor antagonists
CN107405318A (zh) 2014-12-16 2017-11-28 格卢科克斯生物科技有限公司 用于治疗与nadph氧化酶相关的病况的化合物
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤

Also Published As

Publication number Publication date
CN112384497A (zh) 2021-02-19
JP7455762B2 (ja) 2024-03-26
KR20210008493A (ko) 2021-01-22
WO2019215291A1 (en) 2019-11-14
BR112020022406A2 (pt) 2021-04-13
JP2021523135A (ja) 2021-09-02
AU2019267105A1 (en) 2021-01-07
EP3790858A1 (en) 2021-03-17
CA3099093A1 (en) 2019-11-14
US20210171456A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
MX2018008869A (es) Compuestos de benzopirazol y análogos de estos.
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
EA201690752A1 (ru) Ингибиторы g12c kras
TW200518758A (en) HIV replication inhibiting purine derivatives
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
WO2021079196A3 (en) Mettl3 modulators
MX2021016149A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2020011769A (es) Derivados de sulfonamida novedosos que tienen actividad inhibidora selectiva de nox.
MX2021007247A (es) Derivados de rapamicina.
MX2021012105A (es) Compuestos de pirrol.
PH12019501171A1 (en) Pyrido [3, 4-d] pyrimidine derivative and pharmaceutically acceptable salt thereof
PH12021550406A1 (en) Fused ring derivative used as fgfr4 inhibitor
PH12019501566A1 (en) Amide compounds and use thereof
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.